These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21911837)

  • 1. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia.
    Yan XJ; Dozmorov I; Li W; Yancopoulos S; Sison C; Centola M; Jain P; Allen SL; Kolitz JE; Rai KR; Chiorazzi N; Sherry B
    Blood; 2011 Nov; 118(19):5201-10. PubMed ID: 21911837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-related fatigue: Towards a more targeted approach based on classification by biomarkers and psychological factors.
    Schmidt ME; Maurer T; Behrens S; Seibold P; Obi N; Chang-Claude J; Steindorf K
    Int J Cancer; 2024 Mar; 154(6):1011-1018. PubMed ID: 37950650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and cytokine changes associated with symptomatic stages of CLL.
    Agarwal A; Cooke L; Riley C; Qi W; Mount D; Mahadevan D
    Leuk Res; 2014 Sep; 38(9):1097-101. PubMed ID: 25063525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia.
    Yoon JY; Lafarge S; Dawe D; Lakhi S; Kumar R; Morales C; Marshall A; Gibson SB; Johnston JB
    Leuk Lymphoma; 2012 Sep; 53(9):1735-42. PubMed ID: 22475215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-29 Sustains B Cell Survival and Controls Terminal Differentiation via Regulation of PI3K Signaling.
    Hines MJ; Coffre M; Mudianto T; Panduro M; Wigton EJ; Tegla C; Osorio-Vasquez V; Kageyama R; Benhamou D; Perez O; Bajwa S; McManus MT; Ansel KM; Melamed D; Koralov SB
    Cell Rep; 2020 Dec; 33(9):108436. PubMed ID: 33264610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translation of Data from Animal Models of Cancer to Immunotherapy of Breast Cancer and Chronic Lymphocytic Leukemia.
    Gorczynski R
    Genes (Basel); 2024 Feb; 15(3):. PubMed ID: 38540350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.
    Rocha Martins P; Luciano Pereira Morais K; de Lima Galdino NA; Jacauna A; Paula SOC; Magalhães WCS; Zuccherato LW; Campos LS; Salles PGO; Gollob KJ
    Sci Rep; 2023 Dec; 13(1):22634. PubMed ID: 38114557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia.
    Ahmed HA; Nafady A; Ahmed EH; Hassan EEN; Soliman WGM; Elbadry MI; Allam AA
    Ann Hematol; 2024 Mar; 103(3):781-792. PubMed ID: 37946029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the Bone Tissue Microenvironment in Chronic Lymphocytic Leukemia.
    Giannoni P; Marini C; Cutrona G; Sambuceti GM; Fais F; de Totero D
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel clusters of co-expressing cytokines in a diagnostic cytokine multiplex test.
    Polley DJ; Latham P; Choi MY; Buhler KA; Fritzler MJ; Fritzler ML
    Front Immunol; 2023; 14():1223817. PubMed ID: 37600813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib
    Spaner DE; Luo TY; Wang G; Schreiber G; Harari D; Shi Y
    Front Oncol; 2023; 13():1043694. PubMed ID: 37114129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.
    Moore JE; Bloom PC; Chu CC; Bruno JE; Herne CA; Baran AM; Quataert SA; Mosmann TR; Taylor RP; Wallace DS; Elliott MR; Barr PM; Zent CS
    Leuk Res; 2023 Jun; 129():107072. PubMed ID: 37003030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Ryan CE; Brander DM; Barr PM; Tyekucheva S; Hackett LR; Collins MC; Fernandes SM; Ren Y; Zhou Y; McDonough MM; Walker HA; McEwan MR; Abramson JS; Jacobsen ED; LaCasce AS; Fisher DC; Brown JR; Davids MS
    Leukemia; 2023 Apr; 37(4):835-842. PubMed ID: 36717653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
    Gamal W; Sahakian E; Pinilla-Ibarz J
    Blood Adv; 2023 Jun; 7(11):2401-2417. PubMed ID: 36574293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential.
    Yano M; Byrd JC; Muthusamy N
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cytokine levels as possible predicting elements in patients with chronic lymphocytic leukemia.
    Khodashenas M; Rajabian A; Attaranzadeh A; Lavi Arab F; Allahyari N; Allahyari A
    Rev Assoc Med Bras (1992); 2022; 68(10):1364-1368. PubMed ID: 36417637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
    Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
    Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL.
    Bruch PM; Giles HA; Kolb C; Herbst SA; Becirovic T; Roider T; Lu J; Scheinost S; Wagner L; Huellein J; Berest I; Kriegsmann M; Kriegsmann K; Zgorzelski C; Dreger P; Zaugg JB; Müller-Tidow C; Zenz T; Huber W; Dietrich S
    Mol Syst Biol; 2022 Aug; 18(8):e10855. PubMed ID: 35959629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.
    Jung B; Ferrer G; Chiu PY; Aslam R; Ng A; Palacios F; Wysota M; Cardillo M; Kolitz JE; Allen SL; Barrientos JC; Rai KR; Chiorazzi N; Sherry B
    JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35511436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Potential Biomarkers of Prognostic Value in Colorectal Cancer
    Li L; Du X; Fan G
    Front Genet; 2021; 12():787208. PubMed ID: 35251116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.